Back to School: How biopharma can reboot drug development. Access exclusive analysis here

April 29 Quick Takes: After ADC approval, Immunomedics raises $420M for rollout; plus Genespire, Vertex, Ocumension and Cadent

Immunomedics raises $420M to roll out Trodelvy for breast cancer
Immunomedics Inc. (NASDAQ:IMMU) raised $420 million late Tuesday through the sale of 14.7 million shares at $28.50 in a bumped-up follow-on. The price is

Read the full 335 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE